Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: Economic analysis

BMJ (Online)

Volumn 345, Issue 7882, 2012, Pages

  Rozenbaum, Mark H ^a   Van Hoek, Albert Jan ^b   Fleming, Douglas ^c   Trotter, Caroline L ^d   Miller, Elizabeth ^b   Edmunds, W John ^e  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c ROYAL COLLEGE OF GENERAL PRACTITIONERS   (United Kingdom)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CHRONIC KIDNEY DISEASE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG COST; DRUG EFFICACY; ECONOMIC EVALUATION; HEART DISEASE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; INFECTION RISK; LIFE EXPECTANCY; LIVER DISEASE; MAJOR CLINICAL STUDY; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RESPIRATORY TRACT DISEASE; SCHOOL CHILD; SPLEEN DISEASE; STREPTOCOCCUS PNEUMONIA; UNITED KINGDOM; VACCINATION;

AGED; CHILD, PRESCHOOL; CHRONIC DISEASE; COHORT STUDIES; COST-BENEFIT ANALYSIS; ENGLAND; FEMALE; HUMANS; INCIDENCE; INFANT; MALE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; SAMPLING STUDIES; TREATMENT OUTCOME; VACCINATION;

EID: 84868677942     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e6879     Document Type: Article

References (44)

1. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997;46(RR-8):1-24.
2. Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009;180:48-58.
3. Musher DM, Sampath R, Rodriguez-Barradas MC. The potential role for protein-conjugate pneumococcal vaccine in adults: what is the supporting evidence? Clin Infect Dis 2011;52:633-40.
4. Rozenbaum MH, Boersma C, Postma MJ, Hak E. Observed differences in invasive pneumococcal disease epidemiology after routine infant vaccination. Expert Rev Vaccines 2011;10:187-99.
5. French N, Gordon SB, Mwalukomo T, White SA, Mwafulirwa G, Longwe H, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010;362:812-22.
6. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003;349:1341-8. (Pubitemid 37186212)
7. Van Hoek AJ, Andrews N, Waight PA, Stowe J, Gates P, George R, et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect 2012;65:17-24.
8. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011;11:760-8.
9. Jit M. The risk of sequelae due to pneumococcal meningitis in high-income countries: a systematic review and meta-analysis. J Infect 2010;61:114-24.
10. Howard LS, Sillis M, Pasteur MC, Kamath AV, Harrison BD. Microbiological profile of community-acquired pneumonia in adults over the last 20 years. J Infect 2005;50:107-13.
11. Lim WS, Macfarlane JT, Boswell TC, Harrison TG, Rose D, Leinonen M, et al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax 2001;56:296-301. (Pubitemid 32269810)
12. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine 2011;29:9127-31.
13. De Greeff SC, de Melker HE, Spanjaard L, Schouls LM, A van Deursen, SP van Mens, et al. Impact of seven-valent pneumococcal conjugate vaccine on the incidence and serotype distribution of invasive pneumococcal disease in the Netherlands. Poster presented at the European Society for Paediatric Infectious Diseases, June 2011. 2011. The Hague, Netherlands.
14. European Medicines Agency. Assessment report for Prevenar 13. 2010. www.ema.europa. eu/humandocs/Humans/EPAR/Prevenar13/Prevenar13.htm.
15. O'Hagen A, Buck C, Daneshkhah A, Eiser JR, Garthwaite PH, Jenkinson D. Uncertain judgements: eliciting experts' probabilities. Wiley, 2006.
16. Andrews N, Kaye P, Slack M, George R, Miller E. Effectiveness of the 13 valent pneumococcal conjugate vaccine against IPD in England and Wales. 2012. www2.kenes.com/ISPPD/Scientific/Documents/FinalAbstractbook.pdf.
17. Postma MJ. Public health economics of vaccines in the Netherlands: methodological issues and application. J Public Health 2008;16: 267-73.
18. Melegaro A, Choi YH, George R, Edmunds WJ, Miller E, Gay NJ. Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease. BMC Infect Dis 2010;10:90.
19. Office for National Statistics. 2011. www.statistics.gov.uk.
20. Bennett JE, Sumner W, Downs SM, Jaffe DM. Parents' utilities for outcomes of occult bacteremia. Arch Pediatr Adolesc Med 2000;154:43-48. (Pubitemid 30027654)
21. Rozenbaum MH, Sanders EA, van Hoek AJ, Jansen AG, van der Ende A, van den Dobbelsteen G, et al. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ 2010;340:c2509.
22. Oostenbrink R, A Moll HA, Essink-Bot ML. The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis: a head-to-head comparison. J Clin Epidemiol 2002;55:791-9.
23. Curtis L. Unit costs of health and social care. Personal Social Services Research Unit, 2010.
24. Melegaro A, Edmunds WJ. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine 2004;22:4203-14. (Pubitemid 39330342)
25. National Institute for Health and Clinical Excellence. Updated guide to the methods of technology appraisal - June 2008. NICE, 2008.
26. Department of Health. The green book. Immunisation against infectious disease. 2011. http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/prod- consum-dh/groups/dh-digitalassets/@dh/@en/documents/digitalasset/dh-122639.pdf.
27. Begun F, Pebody R. Seasonal influenza vaccine uptake among the 65 years and over and under 65 years at risk in England. Winter season 2009-10. 2010. www.dh.gov.uk/prod-consum-dh/groups/dh-digitalassets/@dh/@en/@ps/documents/ digitalasset/dh-118645.pdf.
28. Hak E, Sanders EA, Verheij TJ, Huijts SM, Gruber WC, Tansey S, et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med 2008;66:378-83.
29. Choi YH, Jit M, Gay N, Andrews N, Waight PA, Melegaro A, et al. 7-valent pneumococcal conjugate vaccination in England and wales: is it still beneficial despite high levels of serotype replacement? PLoS One 2011;6:e26190.
30. Brueggemann AB, Griffiths DT, Meats E, Peto T, Crook DW, Spratt BG. Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential. J Infect Dis 2003;187:1424-32. (Pubitemid 36549688)
31. Trotter CL, Waight P, Andrews NJ, Slack M, Efstratiou A, George R, et al. Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: England and Wales, 1996-2006. J Infect 2010;60:200-8.
32. Flasche S, van Hoek AJ, Sheasby E, Waight P, Andrews N, Sheppard C, et al. Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study. PLoS Med 2011;8:e1001017.
33. Rozenbaum MH, Hak E, van der Werf TS, Postma MJ. Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in the Netherlands. Clin Ther 2010;32:1517-32.
34. Smith KJ, Wateska AR, Nowalk MP, Raymund M, Nuorti JP, Zimmerman RK. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA 2012;307:804-12.
35. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996;313:275-83. (Pubitemid 26254740)
36. Zakikhany K, Degail MA, Lamagni T, Waight P, Guy R, Zhao H, et al. Increase in invasive Streptococcus pyogenes and Streptococcus pneumoniae infections in England, December 2010 to January 2011. Euro Surveill 2011;16:ii19785.
37. Joint committee on vaccination and immunization. Minute of the meeting on Wednesday 13 June 2012. www.wp.dh.gov.uk/transparency/files/2012/07/JCVI- minutes-13-June-2012-draft.pdf.
38. Impfplan Österreich 2012. www.bmg.gv.at/home/Schwerpunkte/ Praevention/Impfen/ Oesterreichischer-Impfplan-2012.
39. http://static.diavgeia.gov.gr/doc/45WWO-2OM. [Greek]2012.
40. Haut conseil de la Sante Publique. 2012. www.hcsp.fr/explore.cgi/ avisrapports?ae=avisrapports&menu=09.
41. Empfehlungen der Sächsischen Impfkommission zur Durchführung von Schutzimpfungen im Freistaat Sachsen [German]. 2012. www.slaek.de/60infos/ infosarzt/36impfen/pdf/e1.pdf.
42. British Medical Association, Royal Pharmaceutical Society of Great Britain. British national formulary . BMA, RPS, 2010. (No 60).
43. Nakagawa F, Lodwick RK, Smith CJ, Smith R, Cambiano V, Lundgren JD, et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS 2012;26:335-43.
44. Harrison KM, Song R, Zhang X. Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States. J Acquir Immune Defic Syndr 2010;53:124-30.